Pharmaceutical composition suitable for intestinal administration

Claim 2

A pharmaceutical composition suitable for intestinal absorption, which comprises a physiologically active substance other than insulin having peptide bonds in its structure and being inactivable by digestive enzymes, and a synthetic chymotrypsin inhibitor.

Claim 3

A pharmaceutical composition as claimed in Claim 1, characterised in that said physiologically active substance is selected from the group consisting of enzymes, peptide hormones, blood components, Krestin, aprotinin and interferon.

Claim 4

A pharmaceutical composition as claimed in Claim 1, or Claim 2, characterised in that said synthetic chymotrypsin inhibitor is a benzoylpiperazine chymotrypsin inhibitor represented by the following formula wherein A is a single bond, or an alkylene, vinylene, -0-alkylene or methine group; R 1 is a bicyclic carbocyclic residue which may partly be saturated and may optionally be substituted by at least one member of the group consisting of lower alkyl, lower alkoxy, oxo and nitro groups, and halogen atoms; a fluorerte residue which may optionally have an oxo group; a fluorenylidene group; an anthracene residue; a phenanthrene residue which may partly be saturated and may optionally be substituted by at least one lower alkyl group; a benzofuran or thianaphthene residue which may optionally be substituted by at least one member of the group consisting of lower alkyl and lower alkoxy groups; a benzopyran or benzazine residue which may partly be saturated and may optionally be substituted by at least one member of the group consisting of oxo and phenyl groups; a phthalimide residue; a benzodiazone residue; an isozazole residue which may optionally be substituted by at least one member of the group consisting of lower alkyl and phenyl groups; and alkylenedioxybenzene residue; or a xanthene residue; and R 2 is a lower alkyl, cycloalkyl, cycloalkylalkyl or aralkyl group.